Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study

TY - JOUR

T1 - Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder

T2 - a head-to-head, randomized, double-blind, phase IIIb study

AU - Dittmann, Ralf W.

AU - Cardo, Esther

AU - Nagy, Peter

AU - Anderson, Colleen S.

AU - Bloomfield, Ralph

AU - Caballero, Beatriz

AU - Higgins, Nicholas

AU - Hodgkins, Paul

AU - Lyne, Andrew

AU - Civil, Richard

AU - Coghill, David

PY - 2013/8/20

Y1 - 2013/8/20

N2 - The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH).

AB - The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH).

U2 - 10.1007/s40263-013-0104-8

DO - 10.1007/s40263-013-0104-8

M3 - Article

C2 - 23959815

SN - 1179-1934

VL - n/a

JO - CNS Drugs

JF - CNS Drugs

M1 - n/a

ER -